Background and Aims: To evaluate the safety and efficacy of 3 additional years of subcutaneous golimumab maintenance in patients with moderately to severely active ulcerative colitis. Methods: The PURSUIT-maintenance long-term extension enrolled patients who had completed placebo or golimumab 50 mg or 100 mg treatment every 4 weeks [q4w] through Week 52 and evaluations at Week 54 [n = 666]; treatment continued through Week 212. Patients receiving placebo were discontinued after study unblinding. Efficacy endpoints, golimumab concentrations, and anti-drug antibodies were summarized as observed for golimumab-induction responders who continued golimumab therapy during the long-term extension. Observations relating to safety were summarized for all treated patients. Results: Overall, 63% of patients who were receiving golimumab at the beginning of the extension remained on treatment through the end of the study. Among all treated patients in the extension, Abbreviations: 6-MP, 6-mercaptopurine; ADAs, anti-drug antibodies; AE, adverse event; AZA, azathioprine; CI, confidence interval; CRP, C-reactive protein; HRQoL, health-related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; IQ, interquartile; ITT, intention-to-treat; LTE, long-term extension; LTF, lost to follow-up; NAb, neutralizing antibody; NMSC, non-melanoma skin cancers; P.Eq, prednisone equivalent; PGA, Physician's Global Assessment; PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; q4w, every 4 weeks; SAE, serious adverse event; SC, subcutaneous; SD, standard deviation; SIR, standardized incidence ratio; TB, tuberculosis; TNF, tumor necrosis factor; UC, ulcerative colitis; UTE, unsatisfactory therapeutic effect; WC, withdrew consent.
Introduction
The golimumab ulcerative colitis [ 2 ) and one 54-week maintenance study (PURSUIT-Maintenance [PURSUIT-M]: NCT00488631 3 ). The PURSUIT-SC and PURSUIT-M studies demonstrated the safety and efficacy of SC golimumab as induction and maintenance therapy in a tumor necrosis factor [TNF]-antagonistnaïve, moderately to severely active UC population who had failed conventional therapy (namely, corticosteroids and/or the immunosuppressants 6-mercaptopurine or azathioprine [AZA] ).
Previously, it was reported that SC golimumab every 4 weeks [q4w] through the first year of the long-term extension [LTE] maintained clinical benefit and reduced corticosteroid use among patients who received golimumab q4w through Week 52 of the 54-week maintenance [i.e. main] study. 4 The primary intent of the current LTE report was to assess the safety profile and maintenance of efficacy of 3 additional years of maintenance therapy with golimumab; the results included herein summarize these data.
Materials and Methods

Study design
All patients who completed either induction study [i.e. PURSUIT-SC or PURSUIT-IV] could participate in the maintenance study. This included patients who responded to golimumab-induction therapy [n = 464] who were randomized at the baseline visit of maintenance, in a 1:1:1 ratio, to receive SC placebo or golimumab [SIMPONI®, Janssen Biotech, Inc., Horsham, PA, USA] 50 or 100 mg q4w, and placebo-induction responders and placebo-and golimumab-induction non-responders who were not randomized. Placebo-induction responders [n = 129] received placebo q4w through Week 52. Golimumab-[n = 405] or placebo-induction [n = 230] non-responders received golimumab 100 mg q4w [ Figure 1A ] during the main study and in the LTE, as described in the Supplemental Appendix [Non-response to Induction Dosing]. Treatment received by patients during the LTE, and an accounting for dose increases during the main study and LTE are shown in Figure 1B .
Patients entered the LTE and received the same therapy they received at Week 52 of the maintenance study [placebo or golimumab 50, 100, or 200 mg] [ Figure 1 ]. The first LTE dose was administered at Week 56 and q4w dosing continued through Week 212, with a final efficacy evaluation at Week 216 and safety evaluation at Week 228.
During the study extension, if a patient's UC disease activity worsened in the opinion of the investigator, the patient was permitted a one-time dose increase of their study agent as follows:
• Patients receiving golimumab 50 mg q4w were eligible to receive golimumab 100 mg q4w.
• Patients receiving golimumab 100 mg q4w were eligible to receive golimumab 200 mg q4w; however, after implementation of a study protocol amendment, a dose increase to golimumab 200 mg was not permitted. Patients who had increased their dose to golimumab 200 mg were required to reduce the dose to 100 mg at the time of the amendment.
• Patients receiving placebo q4w were eligible to receive golimumab 100 mg q4w.
If by 16 weeks following the administration of the adjusted dose, the patient had not shown improvement in their UC disease activity, as assessed by the investigator, they were to be discontinued from the LTE. Treatment assignment remained blinded until the last patient completed Week 54 evaluations and the main study analyses were completed. After unblinding, any patient remaining on placebo was discontinued from the LTE.
The institutional review board or ethics committee at each site approved the protocol, and patients provided written informed consent.
Eligibility
Patients completing treatment through Week 52 and final safety and efficacy evaluations at Week 54 of PURSUIT-M who, in the opinion of the investigator, could benefit from continued treatment had the opportunity to participate in the LTE [ Figure 1B ] for approximately 3 additional years of treatment. No other eligibility criteria were prespecified by protocol for participation in the LTE.
Safety
Patients were queried for adverse events [AEs] and concomitant medication use at each study visit. All patients were routinely assessed for tuberculosis [TB] throughout the LTE. Routine chemistry and hematology laboratory analyses were performed every 3 months.
Pharmacokinetics and immunogenicity
Analyses of serum golimumab concentrations were performed using a validated electrochemiluminescent immunoassay method on the MesoScale Discovery platform. The lowest quantifiable concentration in a sample for this method was 0.03905 μg/, at a minimum required dilution of 1:5. Analysis of anti-drug antibodies [ADAs] was performed using a validated bridging immunoassay, for which the presence of serum golimumab precludes the determination of ADAs.
Efficacy
Disease activity was evaluated using the Physician's Global Assessment [PGA], a subscore of the Mayo score, 5 at Week 56 and every 3 months through Week 216. The PGA has been used previously to evaluate disease activity in a LTE. 6 Health-related quality of life [HRQoL] was assessed with the Inflammatory Bowel Disease Questionnaire [IBDQ] 7 at Week 54 then every 6 months through Week 216 beginning at Week 80. Corticosteroid dose was evaluated at Week 56 and q4w through Week 228, and C-reactive protein [CRP] concentrations were evaluated every 3 months through Week 216.
Statistical methods
For safety analyses, data were summarized from Week 54 through Week 228 for all patients who received at least one administration of study agent during the LTE.
For the placebo, golimumab 50 mg, and golimumab 100 mg groups, a patient with an AE was counted in a treatment group based on the study agent the patient was receiving at the time of AE onset and therefore may have been counted in more than one treatment group. Safety was assessed by summarizing the incidences of AEs, serious AEs [SAEs], infections, serious infections, and injection-site reactions, and events of special interest [malignancy, sepsis, pneumonia, tuberculosis, opportunistic infections, cellulitis, demyelination, congestive heart failure, serum sickness and anaphylactic reactions, and hypersensitivity reactions]. An injection-site reaction was defined as any AE at an injection site that was identified as an injection-site reaction by the investigator. To account for the different durations of follow-up across the treatment groups, the number of AEs per 100 patient-years of follow-up and 95% confidence interval [CI] was calculated for key safety findings. In addition, safety was summarized for patients who underwent a dose adjustment to golimumab 100 mg and those patients who remained on golimumab 100 mg throughout the LTE.
Finally, to assess whether the safety profile of golimumab in UC remained similar with increased duration of exposure, analyses comparing the incidence of key safety events among patients through the first year of therapy (Week 0 of an induction study [PURSUIT-IV or PURSUIT-SC] through Week 54 of PURSUIT-M) and through the subsequent 3 years of the LTE [Weeks 54 through 228] were performed.
For efficacy analyses, patients in the randomized primary analysis population from the main study [i.e. golimumab-induction responders] who continued to receive golimumab in the LTE were evaluated [ Figure 1A ]. Further, efficacy summaries during the study extension are presented for the combined golimumab groups, regardless of dose adjustment.
Descriptive statistics were used to summarize continuous variables. Counts and percentages were used to summarize categorical variables. Demographic and baseline disease characteristics at Week 0 of maintenance were summarized for patients who were treated during the LTE.
The intent of the efficacy analyses in the study extension was to assess maintenance of clinical benefit from the end of the main study [Week 54 ] through the study extension. Analyses are based on observed data at each timepoint [i.e. patients with missing data at a timepoint are not included in the analysis at that timepoint]. It is important to note that patients were selected for participation in the study extension because, in the opinion of the investigator, they had responded to treatment during the main study.
Intention-to-treat [ITT] analyses were also performed. All patients who were randomized at Week 0 of this maintenance study were included in the ITT analyses. In these analyses, treatment failure [patients who discontinued study agent due to lack of therapeutic effect] and missing data rules [last observation carried forward for continuous variables or treated as a non-event for discrete variables] were applied. For dichotomous end points, patients who had a treatment failure were considered as not achieving the respective end point. For continuous end points, patients who had a treatment failure had their Week 0 of an induction value carried forward from the time of the treatment failure.
The placebo group represents a subpopulation of UC patients who were long-term responders to golimumab-induction therapy [i.e. were re-randomized to placebo maintenance and did not dose adjust to golimumab during maintenance] or placebo-induction responders [who did not require dose adjustment to golimumab] with a longer latency of disease, which limits comparisons between the treatment groups. These patients were discontinued from this study after unblinding and were, therefore, not included in the efficacy analyses.
The proportions of patients with PGA scores of 0 [inactive disease] or 1 [mild disease activity] were summarized from Week 54 through Week 216. The proportions of patients who achieved IBDQ scores of ≥170 were summarized from Week 54 through Week 216; IBDQ scores of ≥170 indicate clinical remission. 8 Similarly, CRP concentrations and the proportions of patients who were corticosteroid-free at each timepoint through Week 216 were summarized.
Results
Demographics and baseline characteristics
The PURSUIT-M LTE was conducted at sites in Eastern Europe, North America, Asia Pacific, South Africa, Western Europe, and Israel. Baseline [Week 0 of induction] patient demographics and disease characteristics were generally similar when comparing all patients treated at Week 0 of an induction study 3 with those patients treated in the LTE [ Table 1 ]. On entry into the LTE, median values for golimumab-treated patients were as follows: partial Mayo score of 1.0, a Mayo score of 2.0, an IBDQ score of 191.0, an endoscopy subscore of 1.0, a CRP concentration of 1.6 mg/L, a fecal calprotectin concentration of 132.0 mg/kg, and a fecal lactoferrin concentration of 21.3 μg/mL [ Table 2 ]; two of these deaths were previously reported. 4 Among the seven additional deaths, one patient [cardiac and respiratory insufficiency] received only placebo, while the six remaining patients received golimumab 100 mg; the causes of death included gallbladder cancer, metastatic rectal cancer in a patient diagnosed 10 months after the last golimumab dose, metastatic colon adenocarcinoma, sudden myocardial infarction in a patient with hypertension and mild hypercholesterolemia, accidental nitrous oxide overdose in a patient with no known psychiatric or drug abuse history, and aspiration resulting from complications from an elective colectomy. Among golimumab-treated patients with UC, four patients died from Week 0 of an induction study through Week 54 of the maintenance study, yielding an incidence of 0.37 deaths per 100 patient-years of follow-up, which is consistent with the observed rate of 0.44 per 100 patient-years of follow-up during the study extension. Additionally, the incidence of deaths was comparable across treatment groups in the study extension.
Overall, other AEs of special interest, including malignancies, infections, demyelination, congestive heart failure, hypersensitivity reactions, serum sickness, and anaphylactic reactions, were infrequent [ Table 4 ].
Among patients treated with golimumab in the LTE, 13 patients reported 14 malignancies for an incidence of 0.82 [CI: 0.44, 1.40] per 100 patient-years of follow-up in the combined golimumab group [ Table 4 ]. Three of these malignancies [two non-melanoma skin cancers [NMSCs] and one metastatic colon cancer] were observed between Weeks 54 and 104 and reported previously. 4 Two cases of NMSC [one patient in the golimumab 100 mg group, one with a recurrence in the golimumab 50 mg group], two cases of lymphoma [two patients in the golimumab 100 mg group: one patient receiving concomitant AZA, and one with a history of AZA use], and seven Active TB was reported in four patients [three diagnosed with pulmonary TB; one diagnosed with extrapulmonary TB] during the LTE; all patients were receiving golimumab 100 mg at the time of diagnosis. At screening, none of these patients reported signs or symptoms of active TB, a history of active or latent TB, or recent contact with any persons with active TB, and none had a positive QuantiFERON-TB Gold or purified protein derivative test result. Baseline chest X-rays were read as normal in all patients. All patients received appropriate anti-TB treatment; the three cases of pulmonary TB were reported as recovered, while the case of extrapulmonary TB had not resolved at the last available follow-up.
Three patients developed opportunistic infections during the LTE: Legionella pneumonia, viral meningitis, and primary cytomegalovirus [all receiving golimumab 100 mg at the time of diagnosis]; all patients were treated and recovered.
Two SAEs of demyelinating disorders [paroxysmal paresthesia with tingling in the upper and lower limbs; paresthesias and weakness of the right half of body with magnetic resonance tomography results consistent with multiple sclerosis] were reported during the LTE in patients receiving golimumab 100 mg. One patient was treated with steroids, and both patients' symptoms resolved.
No anaphylactic or serum sickness-like reactions were reported in the LTE. The proportions of treated patients who reported injection-site reactions to golimumab during the LTE were low overall: 1.1% and 2.3% of patients in the golimumab 50 mg and golimumab 100 mg groups, respectively; no patient who was positive for ADAs had an injection-site reaction.
Among patients who continuously received golimumab 100 mg compared with those who dose-adjusted to golimumab 100 mg, rates per 100 patient-years of follow-up for AEs, infections, and injection-site reactions were numerically higher [ Table S2 ].
Adjusting event rates for differential exposure did not suggest that overall event rates were increasing with continued exposure to golimumab beyond 1 year [Table S3 ]. However, it should be noted that this analysis may be limited by reporting bias [e.g. less frequent reporting by study patients of non-serious events] and selection bias [e.g. discontinuation of non-responders prior to Week 54]. Table 5 . Number of patients with one or more malignancies during the study extension compared with the expected number of malignancies from the general US population according to the SEER database; patients who were treated in the study extension. 
Pharmacokinetics and immunogenicity
At the start of the LTE, the median serum golimumab concentration among patients randomized to golimumab 50 mg was approximately half that of patients in the 100 mg group [1.82 μg/mL and 3.49 μg/mL, respectively] [ Figure 2 ]. It should be noted that the Week 54 blood samples were obtained 2 weeks after the administration of golimumab; hence, the serum golimumab concentration at Week 54 was not at trough level, thus explaining the apparent drop in concentration from Week 54 to the next sampling at Week 80. In general, from Week 80 through Week 216 median serum golimumab concentrations remained dose proportional in the golimumab 50 mg and 100 mg groups [ Figure 2] . Overall, the percentage of treated patients with undetectable preadministration serum golimumab concentrations was low; however, of those patients with undetectable pre-administration serum golimumab concentrations, more patients were receiving golimumab 50 mg than 100 mg. At Week 228 [16 weeks after the last study agent administration], the majority of patients in both the golimumab 50 mg and 100 mg groups had undetectable serum golimumab concentrations [77.4% and 51.5%, respectively].
The majority of patients were negative or undetectable with respect to ADAs; 4.4% [4 of 90 patients with appropriate samples] in the golimumab 50 mg group and 3.7% [19 of 514 patients with appropriate samples] in the golimumab 100 mg group were positive for ADAs [ Table 6 ]. Among 23 treated patients who were positive for ADAs during the LTE, 22 were evaluable for neutralizing antibodies [NAbs]; 4 patients were evaluable for NAbs in the golimumab 50 mg group, and 18 patients were evaluable for NAbs in the golimumab 100 mg group. Of these, 3 [75.0%] patients and 15 [83.3%] patients in the golimumab 50 mg and 100 mg groups, respectively, were positive for NAbs.
Efficacy
As described previously, 4 efficacy analyses were based on 200 patients who were randomized to golimumab at maintenance baseline and continued to receive golimumab in the LTE; however, among three sites that were non-compliant with Good Clinical Practice, 5 patients were excluded from these efficacy analyses, yielding 195 patients for these analyses. As nearly 40% of patients discontinued the study agent at or after Week 104, with approximately half of these patients discontinuing due to AEs and unsatisfactory therapeutic effect, and the remainder due to other reasons, such as withdrawal of consent [which may or may not be attributable to the drug] or reasons unrelated to the study agent [i.e. discontinued due to moving away, site closure, or sponsor/investigator or patient decision, patient would like to get pregnant, job issues, or in remission] [ Figure 1A and data on file], efficacy results based on observed analyses are presented below.
Efficacy results for PGA scores based on observed data and ITT analyses are summarized in Table 7 . Results of ITT analyses for all other efficacy endpoints are summarized in the Supplemental Appendix, Tables S4-S7.
Physician's global assessment scores
At Week 54, the proportion of patients with no or mild disease was 90.8% [177/195] Table 7 and Figure 3A ]. Among randomized patients treated with golimumab in the LTE, the mean daily prednisone-equivalent corticosteroid dose [mg/day; excluding budesonide] at Week 56 was 2.13 mg/day. During the LTE, the mean corticosteroid dose was stable through Week 216 and ranged from a low of 0.9 mg/day to a high of 2.4 mg/day [ Table S5 ].
Corticosteroid use
IBDQ scores
At Week 54, the median IBDQ score in the golimumab group was 191.0. During the LTE, the median IBDQ scores were stable through Week 216 and ranged from 192.0 to 198.0 [ Figure 3C ]. At Week 54, the proportion of patients with an IBDQ score of ≥170 was 72.5% [140/193] . During the LTE, the proportion of patients with an IBDQ score of ≥170 was stable through Week 216 and ranged from 70.8% [131/185] to 77.7% [122/157; Figure 3D ].
C-reactive protein concentrations
At Week 54, among randomized patients treated during the LTE, the median CRP concentration was 1.5 mg/L in the golimumab group, and this value was generally maintained during the LTE. During the LTE, the median CRP concentration ranged from 1.3 mg/L to 1.6 mg/L [ Figure 3E ]. 
Dose increase
Discussion
In the main study through Week 54, it was demonstrated that treatment with golimumab was effective in maintaining clinical response and achieving long-term clinical remission and mucosal healing in patients with moderately to severely active UC who had attained clinical response to golimumab induction therapy. 3 Previously, we reported that among patients who did well in the maintenance study, SC golimumab q4w maintained clinical benefit and reduced corticosteroid use through the first year of the LTE. 4 The objective of the current LTE report was to assess the safety, efficacy, and pharmacokinetics through the full 3 years of study treatment in patients who entered the LTE.
Among 1354 patients randomized and treated in the induction studies, 1228 patients participated in the maintenance study through Week 54, of whom 666 patients [54% of those who entered the maintenance study] continued treatment in the LTE. Of the 666 patients who entered and were treated in the LTE, the majority [71.6%] of patients were receiving golimumab 100 mg, with equal proportions of patients [~14%] receiving placebo or golimumab 50 mg. During the LTE, the placebo group had ~2.5 times fewer weeks of follow-up [57.1 weeks] as compared with both golimumab groups [~134 weeks], which was primarily attributable to protocolspecified discontinuation of any patient remaining on placebo at the time of study unblinding. Includes all patients whose last sample could not be classified as negative due to potential interference from circulating active study agent, and excludes patients who were positive at any time during the LTE. Key: LTE, long-term extension.
Accounting for the differences in follow-up between treatment groups, the incidence of infections per 100 patient-years of followup was higher in the golimumab 100 mg group compared with in the golimumab 50 mg and placebo groups. While the incidences of AEs, SAEs, serious infections, and AEs leading to discontinuation were numerically higher in the golimumab 100 mg group compared with in the golimumab 50 mg group, the confidence intervals were overlapping. The higher rate of discontinuation in the 100-mg group may be attributable to the heterogeneity of patients in this group, which included a notable number of patients who were not in clinical response on entry into the maintenance study. Generally similar patterns were observed when comparing the combined golimumab and placebo groups. Additionally, among patients who only received golimumab 100 mg compared with patients who doseadjusted to 100 mg from the golimumab 50 mg and placebo groups, the incidence of key safety events per 100 patient-years of follow-up was higher after accounting for the differences in follow-up between treatment groups. The observed mortality rate of 0.44 per 100 patient-years of follow-up during the study extension is comparable with the rate [0.98 per 100 patient-years of follow-up] reported in a recent large observational study in patients with UC. 9 Overall, the incidence of malignancy was generally comparable between the golimumab 50 mg and 100 mg groups and similar to that expected in the general US population.
The occurrence of opportunistic infections [e.g. Legionella pneumonia, viral meningitis, primary cytomegalovirus infection], TB, and demyelinating events reinforces the importance of treating physicians counselling patients about the risks of treatment with TNFantagonist biologic therapies.
During the LTE, we observed that among randomized patients, continued treatment with SC golimumab q4w was effective in maintaining clinical benefit following completion of the 54-week main study. The sustained PGA scores indicating no to mild disease activity are consistent with the high percentages of patients who maintained IBDQ scores of ≥170 points and who remained corticosteroid-free over time, and for those receiving corticosteroids, their relatively low doses. Sustained decreases in the levels of the objective marker of inflammation, CRP, were also observed. Thus, continued therapy with SC golimumab allowed patients to have reduced exposure to corticosteroids, while maintaining a reduction in disease symptoms and inflammatory burden, and improved HRQoL.
Several important limitations of the design of the LTE are worth noting. It is important to note that patients were selected by the investigator to participate in the LTE because, in their opinion, the patients had benefited from treatment in the PURSUIT-M main study. Overall, nearly 40% of patients discontinued the study agent at or after Week 104, thus limiting the generalizability of the findings in the extension to those patients who responded to and tolerated golimumab in the first year. The LTE had a limited number of placebo patients, with shorter follow-up, which limits the value of direct comparisons between the golimumab and placebo groups, especially for uncommon safety events or events with a long latency. Additionally, this placebo group represents a subpopulation of UC patients who either were long-term golimumab induction responders or long-term true placebo maintenance responders with a longer latency of disease, which further limits efficacy and safety comparisons with the golimumab group.
Due to these limitations, the emphasis of this report focuses on the assessment of safety for the golimumab 50 mg and 100 mg groups, which have similar follow-up during the LTE, with comparisons with the incidence of key safety data that was observed through Week 54, and the general stability of efficacy measures among golimumab-treated patients through the duration of the LTE [i.e. from Week 54 though Week 216].
Dose-proportional trough serum golimumab concentrations were observed with continued SC dosing with golimumab 50 and 100 mg, and continued maintenance therapy resulted in sustained systemic exposure during the LTE. The incidence of ADAs in the LTE was low; however, this was based on a drug-sensitive assay.
With the above limitations noted, the safety profile was similar to that observed through Week 54 and consistent with the current golimumab prescribing information. Patients with moderately to Table 7 . Patients with physician global assessment of no or mild disease activity during the study extension; randomized to golimumab in the maintenance study and who continued receiving golimumab in the LTE.
PGA, %[n/N]
Observed data analysis Intention-to-treat analysis severely active UC who had responded to 52 weeks of treatment and continued to receive golimumab administered SC q4w for an additional 3 years of maintenance showed sustained clinical benefit, as determined by the PGA and IBDQ scores. During the LTE, most patients remained corticosteroid-free. These data continue to support a positive benefit/risk profile for golimumab in the treatment of moderately to severely active UC.
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